JPRN-jRCTs071180065已完成2 期
A Phase 2 study of concurrent combination therapy of TFTD (TAS-102) and bevacizumab in patients of more than 70 years of age with unresectable, advanced/recurrent colorectal cancer (KSCC 1602) - KSCC 1602
Oki Eiji0 个研究点目标入组 39 人开始时间: 2019年3月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 39
研究概览
简要总结
Between January 5, 2017 and March 13, 2018, 39 patients were enrolled in this study. The characteristics of patients were male/female : 17/22, median age : 76.0 (range: 70-88) and Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0/1 : 24/15. The primary endpoint of progression free survival was 8.0 month (80% CI 6.7-11.2).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 70age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients providing the written informed consent.
- •2) Patients are >=70 years of age.
- •3) Patients with colorectal cancer pathologically diagnosed.
- •4) Unresectable colorectal cancer and chemotherapy was not performed as pre-treatment (recurrent patients under adjuvant therapy and within 6 months after adjuvant therapy excluding adjuvant therapy for pathological stage II-III are ineligible)
- •5) Patients with any of the following:
- •(1) Patients who the standard therapy is possible, but does not enforce the standard therapy by the consultation of a investigator and patient (fit)
- •(2) Patients who cannot be received the same standard treatment as a general young people, but can be received some kind of treatment (vulnerable).
- •6) Performance Status (ECOG) 0 or 1
- •7) Patients capable of treatment with oral medicine
- •8) Patients have measurable lesion according to RECIST version 1.1 criteria by trunk part contract-enhanced CT within 28 days before enrollment
- •9) Patients with sufficient organ function
- •10) He/she can accept contraception by an appropriate method from the study drug administration to 6 months after final administration.
- •11) The patient has no severe dysfunction of major organs (bone marrow, liver, kidneys, heart, lungs, etc.) and the patient's laboratory results from up to 14 days prior to enrollment fall within the criteria
- •i) WBC <=12,000/mm^3
- •ii) Neutrophil >=1,500/mm^3
- •iii) Platelet >=100,000/mm^3
- •iv) Hemoglobin >=8.0g/dL
- •v) Total bilirubin <=1.5mg/dL
- •vi) AST, ALT <=100IU/L
- •vii) Albumin >=2.5g/dL
- •viii) Serum creatinine <=1.5mg/dL
- •ix) Creatinine clearance >=60mL/min
排除标准
- •1) Serious drug-induced hypersensitivity (especially, platinum formulation, 5-FU, TFTD)
- •2) Patients received palliative operation (it is eligible at 28 days after the operation with the intestinal anastomosis, at 14 days after colostomy)
- •3) Patients with active infectious disorder
- •4) Patients with uncontrollable hypertension.
- •5) Patients with under treatment by continuous use of insulin or with complication of uncontrollable diabetes mellitus
- •6) Patients with cardiac disorder such as congestive heart failure, angina to need medication, transmural myocardial infarction definitely observed in ECG, clinically apparent valvular disease, symptomatic coronary disease, uncontrollable arrhythmia, anamnesis of myocardial infarction that developed within the past 12 months.
- •7) Patients with severe pulmonary disorder such as interstitial pneumonia, pulmonary fibrosis, severe emphysema.
- •8) Patients with mental disorder or with anamnesis of central nervous system disorder.
- •9) Patients who have the fresh bleeding from gastrointestinal tract needing a transfusion repeatedly.
- •10) Patients who are receiving anticoagulant.
- •11) Patients with watery stool (>=Grade2)
- •12) Active double cancer.
- •Synchronous double cancer and metachronous double cancer within a disease-free interval of 5 years. Lesions consistent with carcinoma in situ or intramucosal carcinoma that have been cured by local treatment are not classified as active multiple cancers.
- •13) Male patients with hope of pregnancy of his partner.
- •14) Patients with cirrhosis or active hepatitis.
- •15) Any other patients who are regarded as unsuitable for this study by the investigators
研究者
相似试验
已完成
2 期
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT03662542Janssen Research & Development, LLC214
招募中
2 期
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinLung Cancer, Small CellNCT06698965Shanghai Chest Hospital52
已完成
2 期
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with metastatic gastric cancerElderly patients with metastatic gastric cancerJPRN-UMIN000009349ational Cancer Center Hospital40
尚未招募
2 期
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell Carcinoma (OSCC)Oropharyngeal Squamous Cell Carcinoma (SCC)Resectable Oral and Oropharyngeal Squamous Cell CarcinomaRecurrent Oral and Oropharyngeal Squamous Cell CarcinomaNCT06728618Shanghai Zhongshan Hospital28
已完成
2 期
Multi-center, phase II study for combination therapy with weekly pacritaxel and 5'-DFUR in patients with unresectable or recurrent gastric cancerAdvanced or recurrent gastric cancerJPRN-UMIN000008631Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine45